Amgen Research GmbH successful in Regensburg
Amgen’s continued delivery of innovative therapeutics through scientific endeavour has changed the practice of medicine and helped millions in their fight against serious illnesses. For more than 25 years, Amgen has been a pioneer in the identification, isolation, production and use of human proteins as therapeutic agents. Today, Amgen scientists work at the cutting edge between the traditional disciplines of chemistry and cellular and molecular biology in an effort to discover and develop innovative treatments for serious illness. Amgen Research GmbH in Regensburg is particularly focused on small-molecule drug discovery, using high-throughput screening to evaluate millions compounds a year. This increases the rate at which Amgen’s deep and broad pipeline of potential new medicines can be converted to a reliable source of proven therapeutic agents.
The German research facility is a key component of Amgen’s international R&D organization, which has developed expertise in several treatment modalities. This enables Amgen to choose the best target for attacking a disease and to use the modality most likely to affect that target. Specialising in small-molecule drug discovery, the Regensburg research facility exemplifies Amgen’s global and cross-functional approach to R&D as it provides extensive support to other R&D facilities in the USA, Canada and the UK. According to Ulrike Schindler, Amgen’s Executive Director Research, “Having a facility in Regensburg is very important to our presence in Europe. We are perfectly placed for collaborations in Western and Central Eastern Europe”.
For more information see: